SCHEMBL2075296

SCHEMBL2075296

Cc1cc(C(=O)CF)ccc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46
TAS1R2 Q8TE23 1/20 0.46
ACHE P22303 1/20 0.45
MCL1 Q07820 1/20 0.44
GAA P10253 2/20 0.43
MGAM O43451 1/20 0.43
AMY1A P0DUB6 1/20 0.43
SI P14410 1/20 0.43
MGAM2 Q2M2H8 1/20 0.43
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
TSHR P16473 1/20 0.41
KMO O15229 2/20 0.40
HDAC3 O15379 2/20 0.40
HDAC4 P56524 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2278168 0.83 CYP3A4 (0.52) CYP1A2CYP3A4CYP2C9CYP2C19TAS1R3
SCHEMBL2097486 0.83 GSK3B (0.53) CYP1A2CYP3A4CYP2C9CYP2C19TAS1R3
SCHEMBL27778655 0.83 CYP1A2 (0.52) CYP1A2CYP3A4CYP2C9CYP2C19TAS1R3
SCHEMBL12430464 0.82 TSHR (0.57) GAAMGAMAMY1ASIMGAM2
SCHEMBL1443571 0.81 CYP1A2 (0.51) CYP1A2CYP3A4CYP2C9CYP2C19TAS1R3
SCHEMBL243504 0.81 GSK3B (0.55) CYP1A2CYP3A4CYP2C9CYP2C19TAS1R3
SCHEMBL7620529 0.81 GSK3B (0.55) CYP1A2CYP3A4CYP2C9CYP2C19TAS1R3
SCHEMBL6279999 0.80 CYP1A2 (0.50) CYP1A2CYP3A4CYP2C9CYP2C19TAS1R3
Hydrochloric Acid SCHEMBL17823285 0.80 CYP1A2 (0.50) CYP1A2CYP3A4CYP2C9CYP2C19TAS1R3
SCHEMBL4621038 0.79 PIM1 (0.55) ACHEMAOAMAOBHDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2114906-B1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS HOFFMANN LA ROCHE (CH) 2014-08-06 EP disclosed
US-8604061-B2 2-aminooxazolines as TAAR1 ligands HOFFMANN-LA ROCHE INC. (US) 2013-12-10 US disclosed
US-20120196903-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS GALLEY GUIDO (DE) 2012-08-02 US disclosed
US-7863444-B2 4-aminopyrrolopyrimidines as kinase inhibitors ABBOTT LABORATORIES (US) 2011-01-04 US disclosed
US-20100120864-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS GALLEY GUIDO 2010-05-13 US disclosed
CN-101600700-A Novel 2-aminooxazolines as TAAR1 ligands for CNS disorders HOFFMANN LA ROCHE (CH) 2009-12-09 CN disclosed
EP-2114906-A1 NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS F. Hoffmann-Roche AG (CH) 2009-11-11 EP disclosed
US-20080261920-A1 2-Aminooxazolines as TAAR1 ligands F. HOFFMANN-LA ROCHE AG (CH) 2008-10-23 US disclosed
WO-2008092785-A1 NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2008-08-07 WO disclosed
US-6150303-A Substituted 3-phenylisoxazolines BASF AKTIENGESELLSCHAFT (DE) 2000-11-21 US disclosed
US-5973164-A Preparation of substituted 3-aryl-5-haloalkyl-pyrazoles having herbicidal activity MONSANTO COMPANY (US) 1999-10-26 US disclosed
US-5969153-A CONDENSING A PHENYL DIKETONE WITH HYDRAZINE IN SOLVENT, THEN ALKYLATION MONSANTO COMPANY (US) 1999-10-19 US disclosed
EP-0923520-A2 PREPARATION OF SUBSTITUTED 3-ARYL-5-HALOALKYL-PYRAZOLES HAVING HERBICIDAL ACTIVITY MONSANTO COMPANY (US) 1999-06-23 EP disclosed
US-5910596-A ESTERS OF 3-(CARBOXYPHENYL)-5-HALOALKYL PYRAZOLES PREPARED BY HALOGENATION OF THE ACID TO FORM ACID HALIDE FOLLOWED BY TREATING WITH AN ALCOHOL/ACYL HALIDE MIXTURE MONSANTO COMPANY (US) 1999-06-08 US disclosed
US-5900489-A BROMINATION MONSANTO COMPANY (US) 1999-05-04 US disclosed
US-5883263-A Preparation of substituted 3-aryl-5-haloalkyl-pyrazoles having herbicidal activity MONSANTO COMPANY (US) 1999-03-16 US disclosed
US-5880290-A FORMING PHENYL-DIKETONES, FORMING, ALKYLATING PYRAZOLES, HALOGENATION OF HETEROCYCLICS, OXIDIZING ALKYL SUBSTITUTED BENZENES AND ESTERIFICATION; REGIOSELECTIVITY FOR 3-ARYL ISOMER BY ALKYLATING THE INTERMEDIATE UNDER ACIDIC CONDITIONS MONSANTO COMPANY (US) 1999-03-09 US disclosed
US-5869688-A OXIDIZING THE ALKYL SUBSTITUENT OF A BENZENE SUBSTRATE IN THE PRESENCE OF A CATALYST MONSANTO COMPANY (US) 1999-02-09 US disclosed
WO-1997048668-A2 PREPARATION OF SUBSTITUTED 3-ARYL-5-HALOALKYL-PYRAZOLES HAVING HERBICIDAL ACTIVITY MONSANTO COMPANY (US) 1997-12-24 WO disclosed
US-5698708-A ALKYLATION; OXIDATION; ESTERIFICATION; CYCLIZATION MONSANTO COMPANY (US) 1997-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120864-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS TAAR1, TAAR5, NPY2R CYP1A2 252/4885CYP3A4 790/4885CYP2C9 571/4885
US-20120196903-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS TAAR1, TAAR5, NPY2R CYP1A2 265/4885CYP3A4 800/4885CYP2C9 610/4885
US-20080261920-A1 2-Aminooxazolines as TAAR1 ligands TAAR1, TAAR5, NPY2R CYP1A2 252/4885CYP3A4 790/4885CYP2C9 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.